Abstract 3982
Background
A special role in the tumour progression is played by heterogeneous components of the microenvironment of tumours, premetastatic tumour niches, influencing which seems likely to change the disease course. Our purpose was to analyze some characteristics of the local cellular immunity in metastatic GC.
Methods
33 GC patients aged 30-80 years were divided into 2 groups: group 1 – M0, non-metastatic GC, n = 17, mean age 61.7±8.9 years (G2 – 11, G3 – 6 patients); group 2 – M1, GC with peritoneal and omentum metastases, n = 16, mean age 58.7±11.5 years (G2 – 7, G3 – 5, G4 - 3 patients). Tumours (T), peritumoral tissues (PT), omentum (O) and peritoneum (P) tissues were studied. Lymphocytes were determined by flow cytometry using FACSCantoII (BD) and T-, B-, NK antibody panels; quantitative content of DN (CD3+CD4-CD8-), DP (CD3+CD4+CD8+) T lymphocytes and regulatory (T-regs) T cells (CD4+CD25+CD127dim) was studied.
Results
Patients with M1 GC demonstrated increased CD3+ lymphocytic infiltration of T, PT, O and P tissues. IRI in M1 O was significantly higher than in M0 (1.95±0.3 vs 0.7±0.2), being similar in other tissues. Levels of DN lymphocytes were lower in O of M1, compared to M0 (7.7±2.5 vs 15.7±5.6, p ≤ 0.05). Contents of NK cells, NKT lymphocytes significantly decreased in O of M1 patients, compared to M0 (3.3≤1.1 vs 14.0≤2.3 and 1.7±0.5 vs 3.8±0.8, respectively). Higher levels of NKT lymphocytes were registered in M1 PT, compared to M0 (3.3±1.1 vs 1.3±0.4), as well as lower levels of NK cells in T (2.3±0.9 vs 5.33±0.2). Percentage of Treg lymphocytes in P and O were significantly lower in M1 than in M0 (respectively, 6.9±1.5 vs 12.6±4.9 and 5.9±1.3 vs 12.6±4.9). Higher amount of B lymphocytes was registered in all tissues of M1 patients, compared to M0, maximal in O (13.1±3.3 vs 3.4±1.5), T (23.5±5.1 vs 17.2±2.3) and P (8.2±3.4 vs 3.5±1.2), while in PT it was lower (15.7±4.2 vs 43.7±4.5).
Conclusions
GC metastasis to the omentum and peritoneum is characterized by a change in their immunological features – a decrease in the tissue level of NK and NKT lymphocytes, a loss in the prevalence of CD3+CD8+ due to an increase in the number of CD3+CD4+ cells, and an increase in the level of CD19 + (B2) lymphocytes. This probably contributes to the appearance of metastatic lesions in these organs in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2667 - The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC).
Presenter: Takeshi Kawakami
Session: Poster Display session 2
Resources:
Abstract
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract